Richard A. Baron Appointed as the CFO and VP of Zynerba Pharmaceuticals, Inc.
Published By : 05 Jan 2015 | Published By : QYRESEARCH
According to a new report released today, Zynerba Pharmaceuticals, Inc. announced the appointment of vice president as Richard A. Baron and CFO chief financial officer effective from January 5, 2015. He has more than 30 years of experience in the pharmaceutical industry, particularly in the field of executive finance leadership for pharmaceutical, early-stage, and healthcare companies.
Zynerba Pharmaceuticals, Inc., is a specialty pharmaceutical company that is devoted to the growth and development of innovative transdermal synthetic cannabinoid treatments.
However, prior to joining Zynerba, Mr. Baron had experience as CFO of Globus Medical GMED and Senior Vice President in the same medical facility. GMED is a medical device company (-0.08%) – a market cap of over $2 billion.
He also served as CFO and Vice President of Avid Radiopharmaceuticals – a huge biotech company that was traded to Eli Lily in 2011 for around $300 million with a definite benchmark of $800 million.
In addition to his achievements, Mr. Baron also served as CFO for multiple life sciences companies such as Animas Corporation that was sold to Johnson and Johnson in the year 2007.
Richard A. Baron has qualifications as a BS in Economics and focus in Accounting from the Wharton School of the University of Pennsylvania.
Zynerba chief executive officer and chairman-Armando Anido said Rick has set a brilliant track record of successfully serving the emerging companies to grow and enhance to the next levels through different strategic financing. He will be valued more than a member on the Zynerba team as he is joining with immediate effect in the coming months. His efforts will take the work of the institution to the next stage.